Real-world Outcomes among Eyes with Center-Involving Diabetic Macular Edema and Good Visual Acuity

References

• Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653–64. doi:10.2337/diacare.26.9.2653.
   PubMed Web of Science ®Google Scholar
• Organization WH. Global report on diabetes: world health organization. 2016.
   Google Scholar
• Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64. doi:10.2337/dc11-1909.
   PubMed Web of Science ®Google Scholar
• Varma R, Bressler NM, Doan QV, Gleeson M, Danese M, Bower JK, Selvin E, Dolan C, Fine J, Colman S, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(11):1334–40. doi:10.1001/jamaophthalmol.2014.2854.
   PubMed Web of Science ®Google Scholar
• Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M, et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019;321(19):1880–94. doi:10.1001/jama.2019.5790.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. doi:10.1016/j.ophtha.2011.12.039.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609–14. doi:10.1016/j.ophtha.2010.12.033.
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–22. doi:10.1016/j.ophtha.2013.02.034.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–203.
   PubMed Web of Science ®Google Scholar
• Busch C, Fraser-Bell S, Zur D, Rodríguez-Valdés PJ, Cebeci Z, Lupidi M, Fung AT, Gabrielle PH, Giancipoli E, Chaikitmongkol V, et al. Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study. Acta Diabetol. 2019;56(7):777–84. doi:10.1007/s00592-019-01310-z.
   PubMed Web of Science ®Google Scholar
• Kiss S, Chandwani HS, Cole AL, Patel VD, Lunacsek OE, Dugel PU. Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema. Clin Ophthalmol. 2016;10:2443–53. doi:10.2147/OPTH.
   PubMed Web of Science ®Google Scholar
• Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net protocol T. Curr Opin Ophthalmol. 2017;28(6):636–43. doi:10.1097/ICU.0000000000000424.
   PubMed Web of Science ®Google Scholar
• Brodie SE, Gupta PC, Irsch K, Jackson ML, Mauger TF, Strauss L, Thall EH, Young JA. Clinical optics. San Francisco (USA): American Academy of Ophthalmology; 2018.
   Google Scholar
• Channa R, Sophie R, Khwaja AA, Do DV, Hafiz G, Nguyen QD, Campochiaro PA, READ-2 study group. Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. Eye (Lond). 2014;28(3):269–78. doi:10.1038/eye.2013.245.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A, RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121(1):209–19. doi:10.1016/j.ophtha.2013.08.038.
   PubMed Web of Science ®Google Scholar
• Lukic M, Williams G, Shalchi Z, Sim D, Patel PJ, Keane PA, Hykin PG, Sivaprasad S, Menon D, Bruynseels A, et al. Intravitreal aflibercept for diabetic macular oedema: moorfields’ real-world 12-month visual acuity and anatomical outcomes. Eur J Ophthalmol. 2019;1120672119833270. https://www.ncbi.nlm.nih.gov/pubmed/30808179
   Web of Science ®Google Scholar
• Ozkaya A, Ozveren M, Demircan A. The real life data of ranibizumab use among the diabetic macular edema patients in Turkey: documenting the improvement with clinical optimization during three consecutive years. Saudi J Ophthalmol. 2018;32(3):175–79. doi:10.1016/j.sjopt.2018.04.005.
   PubMed Web of Science ®Google Scholar
• Patrao NV, Antao S, Egan C, Omar A, Hamilton R, Hykin PG, Sivaprasad S, Rajendram R, Moorfields Diabetic Macular Edema Study Group. Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom national health service setting. Am J Ophthalmol. 2016;172:51–57. doi:10.1016/j.ajo.2016.09.002.
   PubMed Web of Science ®Google Scholar
• Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, Wells JA 3rd, Diabetic Retinopathy Clinical Research Network. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012;130(9):1153–61. doi:10.1001/archophthalmol.2012.1107.
   PubMedGoogle Scholar
• Bressler SB, Odia I, Maguire MG, Dhoot DS, Glassman AR, Jampol LM, Marcus DM, Solomon SD, Sun JK, Diabetic Retinopathy Clinical Research Network. Factors associated with visual acuity and central subfield thickness changes when treating diabetic macular edema with anti-vascular endothelial growth factor therapy: an exploratory analysis of the protocol T randomized clinical trial. JAMA Ophthalmol. 2019;137(4):382–89.
   Web of Science ®Google Scholar
• Eriksson U, Alm A, Bjarnhall G, Granstam E, Matsson AW. Macular edema and visual outcome following cataract surgery in patients with diabetic retinopathy and controls. Graefes Arch Clin Exp Ophthalmol. 2011;249(3):349–59. doi:10.1007/s00417-010-1484-9.
   PubMed Web of Science ®Google Scholar
• Takamura Y, Kubo E, Akagi Y. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Ophthalmology. 2009;116(6):1151–57. doi:10.1016/j.ophtha.2009.01.014.
   PubMed Web of Science ®Google Scholar
• Litvin TV, Bresnick GH, Cuadros JA, Selvin S, Kanai K, Ozawa GY. A revised approach for the detection of sight-threatening diabetic macular edema. JAMA Ophthalmol. 2017;135(1):62–68. doi:10.1001/jamaophthalmol.2016.4772.
   PubMed Web of Science ®Google Scholar